COO

Business Profile & Competitive Position

The Cooper Companies, Inc. operates in the Healthcare sector under the Medical – Instruments & Supplies industry. It is a global medical device company based in San Ramon, California, with two main businesses: CooperVision, which develops, manufactures and markets single-use, two-week and monthly contact lenses plus specialty eyecare products; and CooperSurgical, which supplies more than 600 products and services focused on fertility and women’s health.

CooperVision’s portfolio includes silicone hydrogel lenses, orthokeratology and scleral lenses, and the myopia-management product MiSight 1 day. CooperSurgical covers gynecology, obstetrics, contraception, labor and delivery, cord blood and tissue storage, IVF support, donor gametes, cryopreservation and genomic services. According to the company’s latest 10-K, its products reach more than 130 countries and impact more than fifty million lives annually.

The financial ratios reinforce what the product mix implies: a net margin of 13.5% points to pricing discipline and reasonably efficient manufacturing, while an ROE of 6.9% is more modest and suggests the company is capital-intensive, acquisition-supported, or carrying significant equity on the balance sheet. The MiSight 1 day lens is approved by the FDA, Chinese NMPA and Japanese MHLW to slow myopia progression in age-appropriate children, which is a real regulatory moat. Overall, Cooper’s competitive position rests on a broad, regulated product lineup, global distribution scale and a dual-segment model that ties recurring consumer contact-lens sales to procedurally driven fertility and women’s health revenue.

Financial Posture

Cooper Companies carries a market capitalization of $11.6 billion and trades at a trailing P/E of 20.8. The stock’s beta is 0.82, meaning it historically has moved less than the overall market, consistent with a defensive, healthcare-oriented cash-flow profile. The most recent price is $61.02, with RSI at 60.1 and the 50-day EMA at $60.71, putting the shares roughly in line with their short-term moving average.

The 13.5% net margin supports profitability, and the 6.9% ROE reflects steady but not exceptional capital returns. The 20.8 P/E multiple sits in a middle ground for the medical-device space: not a deep-value multiple, but also not demanding enough to require heroic growth assumptions. Combined with the low beta, the current financial posture looks like that of a mid-cap, defensive-growth healthcare company—profitable, globally diversified and valued modestly relative to the broader equity market.

Strategic Priorities & Outlook

The company’s most recent 10-K filing outlines a clear set of near-term operational priorities. CooperVision is focused on expanding worldwide market penetration of recently introduced products and building share in both existing and emerging markets. To support that growth, it is increasing investment in distribution and packaging capabilities. It is also investing to develop the myopia management category by educating eye care practitioners, patients and families.

On the CooperSurgical side, the company expects to continue investing in the business and to pursue strategic transactions that expand its integrated solutions model within fertility and women’s health. A notable operational fact in the filing is that approximately 500 employees work in research and development across both segments. These priorities signal a company prioritizing category development and global distribution over short-term margin extraction, with CooperSurgical explicitly looking at M&A to deepen its platform.

Macro & Geopolitical Exposure

As a Medical – Instruments & Supplies company, Cooper faces the macro exposures typical of regulated global device manufacturers. These include U.S. FDA and foreign-equivalent approvals, product recalls, reimbursement and payor policy changes, and evolving clinical guidelines. Because more than 130 countries are part of the revenue base, currency translation is a recurring factor; a stronger U.S. dollar can compress reported overseas sales, while a weaker dollar can inflate them.

Trade policy also matters: tariffs or duties on polymers, packaging materials and finished medical devices can affect input costs, as can broader supply-chain disruptions for plastics and other raw materials. In the fertility segment, demand can be influenced by macroeconomic confidence, demographic trends and regional funding for IVF services. None of these are unique to Cooper Companies, but they are all genuine risks attached to the industry classification.

Recent Developments

The most prominent recent news flow has been legal rather than operational. On October 22, 2026, both globenewswire.com and prnewswire.com carried releases from the Rosen Law Firm and Pomerantz Law Firm, respectively, stating they were investigating The Cooper Companies on behalf of investors and inviting shareholders who had suffered losses to contact them. A second Rosen Law Firm release followed on October 25, 2026 via globenewswire.com. A parallel release also appeared on October 23, 2026 from newsfilecorp.com.

These are securities-class-action investigation notices, not judgments or settled allegations. Still, repeated headlines from investor-counsel firms create headline risk and can weigh on sentiment, especially around earnings windows when options and realized volatility are already elevated.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Cooper Companies has beaten consensus earnings estimates 8 out of 8 times, with an average positive surprise of 4.2%. On the surface that looks like a textbook beat stock. Yet the average five-day price move after those reports is –2.34%, classified as a downward post-earnings drift.

The most recent quarters highlight the disconnect. On September 9, 2026, COO reported actual EPS of $1.15 against an estimate of $1.12, a 2.7% beat, but the stock fell –14.67% the next day and –13.97% over the following five sessions. The previous report, on June 4, 2026, showed a much larger beat—actual EPS of $1.21 versus $1.10 estimated, a 10.0% surprise—and the stock rallied +8.58% the next day and +8.85% over five days. Before that, on March 5, 2026, EPS of $1.10 beat $1.03 by 6.8%, yet the stock dropped –4.55% the next day and –10.82% over five days. The December 4, 2025 quarter—actual EPS $1.15 vs. $1.11, a 3.6% beat—posted a five-day gain of +6.59%.

The takeaway is that beating the printed estimate has not reliably produced a post-earnings pop. The market’s real expectation appears to be set more by forward guidance, segment commentary, margin trajectory and any legal or M&A overhang than by the headline EPS number alone. The next scheduled report is December 3, 2026, after the closing bell, with the consensus EPS estimate currently at $1.07.

For a fuller picture of how institutional analysts are interpreting the latest quarter, legal headlines and strategic direction, review the complete institutional verdict on The Cooper Companies, which aggregates analyst notes, estimate revisions and contextual commentary for a deeper dive.